Report: New Concepts in Cancer Therapeutics from Piribo.com

1 Executive Summary
2 Cancer Highlights
3 Methodology
4 Table of Contents
- 4.1 List of Boxes
- 4.2 List of Figures
- 4.3 List of Tables
5 Global Cancer Trends
- 5.1 The Global Cancer Therapeutic Market, Drivers and Blockbuster drugs
6 Strategic Keys & Insights to the Global Cancer Pipeline
- 6.1 Historical FDA Approvals for Cancer Therapeutics
7 Changes in Clinical Trial Design, Endpoints & Markers
- 7.1 Key Source of Trial Inconsistency
- 7.2 Toxicity: Safety & Tolerability
- 7.3 Maximal Tolerated Dose
  - 7.3.1 Dose Limiting Toxicity
- 7.4 Efficacy: Add-On Drug
- 7.5 Discussions for a shift in cancer trial design
  - 7.5.1 Biologically defined surrogate markers
  - 7.5.2 Molecular Profiling of Drug Targets and "Best Fit Drugs"
  - 7.5.3 Markers of Efficacy
  - 7.5.4 Heterogenity; tumors & drugs
  - 7.5.5 The risk of missing good leads is a devastating waste of property
8 Treatment regimes
- 8.1 Breast cancer
  - 8.1.1 Drugs approved by FDA
  - 8.1.2 A Shift in Standard Treatment Recommendations
  - 8.1.3 Clinical Progress of the Established Drugs
  - 8.1.4 Estrogen receptor modulators
  - 8.1.5 Aromatase Inhibitors
  - 8.1.6 Herceptin
- 8.2 Colorectal cancer
  - 8.2.1 Capecitabine
  - 8.2.2 Irinotecan
  - 8.2.3 Bevacizumab
  - 8.2.4 Oxaliplatin
  - 8.2.5 Cetuximab
  - 8.2.6 Levamisole
- 8.3 Melanoma
  - 8.3.1 Dacarbazine
  - 8.3.2 Cisplatin BioSeeker Group 7 No. 9
  - 8.3.3 Carboplatin
  - 8.3.4 Carmustine
  - 8.3.5 Melphalan
  - 8.3.6 Paclitaxel
  - 8.3.7 Tamoxifen
  - 8.3.8 Temozolomide
  - 8.3.9 Vinblastine/Vinorelbine
  - 8.3.10 Virulizin
  - 8.3.11 Melacine
  - 8.3.12 Alfanative (Multiferon)
  - 8.3.13 Proleukin or (Macrolin)
  - 8.3.14 Ceplene Maxamine
- 8.4 Lung cancer
  - 8.4.1 General
  - 8.4.2 Platinum-based chemotherapy
  - 8.4.3 Docetaxel
  - 8.4.4 Paclitaxel
  - 8.4.5 Vinorelbine
  - 8.4.6 Gemcitabine
  - 8.4.7 Gefitinib
- 8.5 Leukemia
  - 8.5.1 ALL
  - 8.5.2 AML
  - 8.5.3 CML
    - 8.5.3.2 CML R&D
  - 8.5.4 Prostate cancer
    - 8.5.4.1 Zoladex, Goserelin
    - 8.5.4.2 Finasteride, Proscar, Propecia
    - 8.5.4.3 Progress Analysis: Casodex, (R)-bicalutamide
- 8.6 The Anticancer Pipeline: General trends
  - 8.6.1 Therapeutic Antibodies
  - 8.6.2 Immunotherapies
  - 8.6.3 Gene therapies
    - 8.6.3.1 Viral vectors
    - 8.6.3.2 Synthetic Delivery Systems
  - 8.6.4 Vascular targeting & Antiangiogenesis
  - 8.6.5 Protein kinase inhibitors
    - 8.6.5.1 CDK Inhibitors
    - 8.6.5.2 Other Types of Protein Kinase Inhibitors
  - 8.6.6 Apototic inducers
  - 8.6.7 Multipathway Regulators
  - 8.6.8 Endothelin Receptor Antagonists
  - 8.6.9 Inflicting DNA Synthesis
  - 8.6.10 Targeting Hormone Action
9 Progress on New Drugs and Targets
- 9.1 Hypoxic Activated Prodrug
- 9.2 New Kinase Inhibitors
  - - 9.2.1.1 Progress Analysis: SKI-606
    - 9.2.1.2 Progress Analysis: BMS-354825
  - 9.2.2 Aurora Kinase Inhibitors
    - 9.2.2.1 Aurora in Clinical Development
  - 9.2.3 New CDK Inhibitors
    - 9.2.3.1 Progress Analysis: CYC202
    - 9.2.3.2 Progress Analysis: BMS-387032
- 9.3 Wanted: Insulin-like Growth Factor 1 Receptor
- 9.4 Novel Apoptosis Inducers - The Killer?
  - 9.4.1.1 Progress Analysis: Programmed Cell Death 1 Drug
  - 9.4.1.2 Progress Analysis: Programmed Cell Death 8 Drug
- 9.5 Novel Taxanes
- 9.6 PEG-camptothecin Conjugates
- 9.7 Hitting on Kinesins
  - 9.7.1.1 Progress Analysis: SB-715992
- 9.8 Antiangiogenesis through Targeting Cell Adhesion
  - 9.8.1.1 Progress Analysis: Exherin
  - 9.8.1.2 Progress Analysis: N-cadherin antagonists
  - 9.8.1.3 Progress Analysis: OB-cadherin antibodies
  - 9.8.1.4 Progress Analysis: VE-cadherin antibodies
- 9.9 Molecular Target of Rapamycin.
- 9.10 Other New Interesting Anticancer Drug Targets
  - 9.10.1.1 Progress Analysis: n-CoDeR anti Angiomotin
  - 9.10.1.2 Progress Analysis: Chemokine, ELC/CCL19
  - 9.10.1.3 Progress Analysis: LY 2275796
  - 9.10.1.4 Progress Analysis: Anti-CD32 MAb
  - 9.10.1.5 Progress Analysis: HAS2 inhibitor
  - 9.10.1.6 Progress Analysis: MDX-1307
  - 9.10.1.7 Progress Analysis: Ubiquitin modulators
10 Novel Screening Technologies
- 10.1 The Omics Era
- 10.2 Genomics Information Providers
- 10.3 Selection of Targets in Drug Discovery
  - 10.3.1 Therapeutic Value, Essential in Lead Optimization.
  - 10.3.2 Virtual Library Screening
  - 10.3.3 Drug Discovery through Three-Dimensional Information
  - 10.3.4 In Silico Evaluation of ADME-Tox/Efficacy
    - 10.3.4.1 Allosteric Binding Sites
    - 10.3.4.2 New Family of Membrane-Bound Serine Proteases
- 10.4 Power in Combinatorial Synthesis
  - 10.4.1 From High- Throughput Screening To High-Content Screening
    - 10.4.1.1 Cell based approaches vs Biochemical screening
  - 10.4.2 Aptamer In Drug Discovery
  - 10.4.3 Cytostatic Agents, A Need For Longer-Term Model System
  - 10.4.4 Explanation to The Anti-Angiogenetic Clinical Failures
- 10.5 A Need to Develop New Mouse Models
  - 10.5.1 RNA interference-mediated inhibition
- 10.6 Progress in Assay Development
11 Selected Company profiles
- - 11.1.1 Adventrx Pharmaceuticals Inc
  - 11.1.2 Amgen Inc
  - 11.1.3 AVI BioPharma
  - 11.1.4 Bioaccelerate Inc
  - 11.1.5 Cancer Research Technology
  - 11.1.6 Celgene Corporation
  - 11.1.7 F Hoffmann-La Roche Ltd
  - 11.1.8 GlaxoSmithKline Plc
  - 11.1.9 Igeneon AG
  - 11.1.10 Johnson & Johnson BioSeeker Group 9 No. 9
  - 11.1.11 Novartis International AG
  - 11.1.12 Onyvax Ltd
  - 11.1.13 Pfizer Inc
12 Disclaimer
13 Drug Index
14 Company Index
List of Boxes
- Box 1: Defining Limiting Toxicity
- Box 2: Critical Risk Factors for Development of Melanoma
- Box 3: Major Treatment Regimes
- Box 4: CLL Staging System
- Box 5: General Structure for Treatment of AML
- Box 6: Difficulties Facing Anti-angiogenesis
- Box 7: New Target - EGF Like Domain
- Box 8: Kinesin Development Patents
- Box 9: Competitive Patents to those of Adherix
- Box 10: Important Targets in Cancer Drug Discovery
- Box 11: DS Modelling Components
List of Figures
- Figure 1: Growth of Cancer Therapeutic Companies, 1985-2005
- Figure 2: The Global Cancer Pipeline by 2005
- Figure 3: Summarized Description of Colon Cancer Development and Clinical Outcome
- Figure 4: Generalized Illustration, Depicting the Key Elements Involved in the Apoptotic Pathways
- Figure 5: Phases in the drug discovery process
- Figure 6: Analysis of Risk/Return for new chemical entities. Marketed between the years 1975 to 1984
- Figure 7: ADME/Tox Evaluation Process
List of Tables
- Table 1: Anti-cancer Agents with Blockbuster Status
- Table 2: The Ten Highest Cancer Indications in Number of Drugs in Development
- Table 3: Line of Current Cancer Therapeutics
- Table 4: Cancer Therapeutic Strategies of Specific Interest
- Table 5: Novel Approaches to Cancer Therapy
- Table 6: Key Parameters for Designing a Phase II Study
- Table 7: Available BioMarkers
- Table 8: Clinical Practise Guidelines
- Table 9: 5-year Survival Rate in CRC
- Table 10: Risk Factors for Colon Cancer Development
- Table 11: Summary of Colorectal Cancer Regimens
- Table 12: Summary of Chemotherapy Drugs
- Table 13: Definition and Description of Stages of Melanoma
- Table 14: Prognosis of the 4 Stages of Malignant Melanoma
- Table 15: Approved Cytotoxic Drugs for Treatment of Melanoma
- Table 16: Prostate Clinical Studies
- Table 17: Summary of Strategies Enhancing Antibody Function BioSeeker Group 10 No. 9
- Table 18: Therapeutic Interventions for Exploiting Differences Between Normal and TumorEndothelium
- Table 19: CDK Inhibitors
- Table 20: Other Kinase Inhibitors in Development
- Table 21: Common Gene/Protein Defects in Apoptotic Pathways
- Table 22: Overview of Apoptosis Targets in Development
- Table 23: Key Industry Releated R&D
- Table 24: Hormone Modulating Drugs
- Table 25: AQ4N Research
- Table 26: Src & Abl Related R&D Projects
- Table 27: Companies with Interest in Aurora Kinase
- Table 28: CDK inhibitors Drugs under Development
- Table 29: Inhibitors of IGF and IGF-R in Development
- Table 30: Overview of Apoptosis Drugs - Preclinical to Marketed
- Table 31: Biological Drugs as Apoptotic Inducers
- Table 32: Selected Competing Taxane Drugs
- Table 33: Selection of Camptothecin Derivates
- Table 34: Kinesin Related R&D Projects
- Table 35: Antiangiogenesis Compounds Targeting Cell Adhesion
- Table 36: Other Cell Adhesion Related Projects
- Table 37: Selected Rapamycin Analogs
- Table 38: New Anticancer Drug Target Emerging 2004-2005
- Table 39: Relative Strengths and Weaknesses of Tools used in Structural Proteomics
- Table 40: Selected Proteomics Drug Discovery Companies
- Table 41 Biochemical Assay Methods that are Used for High-Throughput Screening

Cancer

New Concepts in Cancer Therapeutics

Price £1,665.00

Summary

Scope of this report

Research and analysis highlights

Key reasons to read this report

Content

Bookmark this Product